Monthly Prescribing Reference

Susvimo Approved for Patients With Diabetic Retinopathy

Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks (approximately 9 ...
Business Wire

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...
Business Wire

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
Healio

FDA approves Susvimo for treatment of diabetic retinopathy

Please provide your email address to receive an email when new articles are posted on . The approval is based on positive 1-year data from the phase 3 Pavilion study. This is Susvimo’s third ...
Hosted on MSN

Genentech reports five-year data from trial of Susvimo for wet AMD

Roche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and efficacy of Susvimo (ranibizumab injection) for treating wet age-related ...
Healio

FDA approves Susvimo for diabetic macular edema

Please provide your email address to receive an email when new articles are posted on . The approval was supported by 1-year results from the phase 3 Pagoda study. Susvimo is also approved for wet age ...
clinicaladvisor.com

Susvimo Approval Expanded to Include Diabetic Macular Edema

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...
Monthly Prescribing Reference

Susvimo Available Again for Wet Age-Related Macular Degeneration

Credit: Genentech. In 2022, a voluntary recall was initiated due to some Susvimo implants not performing to Company standards. Genentech is reintroducing Susvimo ® (ranibizumab), a refillable ocular ...
FiercePharma

Roche gains label expansion for eye implant Susvimo to treat diabetic macular edema

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...
Nasdaq

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...
Nasdaq

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...